What's new for 'Trypanosomatids' in PubMed

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.

Sender's message:

Sent on Friday, 2010 Jun 11
Search kinetoplastids OR kinetoplastid OR Kinetoplastida OR "trypanosoma brucei" OR leishmania OR brucei OR leishmaniasis OR "African trypanosomiasis"
Click here to view complete results in PubMed. (Results may change over time.)
To unsubscribe from these e-mail updates click here.

PubMed Results

Items 1 - 6 of 6

1.	Int J Dermatol. 2010 May;49(5):565-9. Oral miltefosine in post-kala-azar dermal leishmaniasis - experience in three cases. Khandpur S, Chaturvedi P, Kumar U, Khaitan BK, Samantaray JC, Sharma VK. Departments of Dermatology & Venereology, All India Institute of Medical Sciences, New Delhi, India.
	PMID: 20534094 [PubMed - in process]
	Related citations

2.	Int J Dermatol. 2010 May;49(5):557-61. Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006. Sharifi I, Fekri AR, Aflatoonian MR, Khamesipour A, Mahboudi F, Dowlati Y, Nadim A, Modabber F. Leishmaniasis Research Center, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran. Abstract Background Leishmaniasis recidivans (LR) is a rare phenomenon in the world with high morbidity in children. Methods Overall 22 838 school children were examined during 1994-2006. Diagnosis was performed by combination of methods as clinical appearance, direct smears, cultures, polymerase chain reaction (PCR) and histology. Results Ninety-eight cases were diagnosed as LR with duration of lesions varying from 2 to 8 years and diameter of lesions 1-5 cm, yellowish-brown appearance with papules around or in the scar. Most of the lesions (95%) were on the face. No amastigote was found in direct smears. Identification of nine random isolates by PCR confirmed all species to be L. tropica. Tissue sections showed typical granulomatous reactions with various inflammatory cells but no visible amastigote was seen. Conclusions The presence of LR as an important cause of morbidity has future implications for treatment regimens and immunoprophylaxis.
	PMID: 20534092 [PubMed - in process]
	Related citations

3.	Int J Dermatol. 2010 May;49(5):549-51. Co-infection of mucosal leishmaniasis and extra pulmonary tuberculosis in a patient with inherent immune deficiency. Rathnayake D, Ranawake RR, Sirimanna G, Siriwardhane Y, Karunaweera N, De Silva R. Dermatology unit, The National Hospital of Sri Lanka. Abstract Background In Sri Lanka, cutaneous leishmaniasis is a well-established disease caused by Leishmania donovani. Only a few cases of visceral disease and mucosal localization have been reported to date. Case report A 52-year-old man presented with severe local destruction of his upper and lower lip and total destruction of the anterior nasal septum and was diagnosed with mucosal leishmaniasis. The causative organism was confirmed to be Leishmania donovani. In addition he had tuberculous lymphadenitis and inherent immune deficiency. His previous medical history was unremarkable. The patient was successfully treated with intramuscular sodium stibogluconate. Conclusion The clinical picture and satisfactory treatment response to antimony are similar to mucosal leishmaniasis caused by L. donovani reported in India and Sudan and with the absence of primary skin lesions make it different from new world mucosal leishmaniasis. Even though leishmania and tuberculous co-infection has been reported in association with HIV this has not been reported in inherent immune deficiency.
	PMID: 20534090 [PubMed - in process]
	Related citations

4.	Transpl Infect Dis. 2010 May 30. [Epub ahead of print] Expanded infectious diseases screening program for Hispanic transplant candidates. Fitzpatrick MA, Caicedo JC, Stosor V, Ison MG. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Abstract M.A. Fitzpatrick, J.C. Caicedo, V. Stosor, M.G. Ison. Expanded infectious diseases screening program for Hispanic transplant candidates. Transpl Infect Dis 2010. All rights reserved Abstract: Most guidelines for pre-transplant screening recommend enhanced screening among patients with potential exposure to such pathogens as Strongyloides stercoralis and Trypanosoma cruzi, the cause of Chagas disease. The incidence of these diseases in the Hispanic immigrant population has not been extensively studied. Transplant candidates who were evaluated by our program's Hispanic Transplant Program were referred for expanded infectious disease screening including Mycobacterium tuberculosis, S. stercoralis, Leishmania, and T. cruzi. Between December 2006 and December 2008, 83 patients were screened. Most were from Mexico but we also screened patients from Ecuador, Puerto Rico, and Peru. Most patients lived in urban locations before moving to the United States. Latent tuberculosis infection (LTBI) was found in 20%, and 6.7% had serologic evidence of S. stercoralis infection. These patients underwent treatment of latent infection without difficulty. To date, 14 patients have undergone living-donor kidney transplantation. Two of these patients had positive Leishmania titers and are being followed clinically, 1 was treated for S. stercoralis, and 2 were treated for LTBI pre-transplant. All have done well without evidence of screened pathogens an average of 348 days (range 65-766 days) post transplant. Expanded screening identifies endemic infections in the Hispanic immigrant population that can be treated before transplant, thereby minimizing post-transplant infectious complications.
	PMID: 20534036 [PubMed - as supplied by publisher]
	Related citations

5.	Transpl Infect Dis. 2010 May 30. [Epub ahead of print] Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients. Vigna E, De Vivo A, Gentile M, Morelli R, Lucia E, Mazzone C, Recchia AG, Vianelli N, Morabito F. Unità Operativa Complessa di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy. Abstract E. Vigna, A. De Vivo, M. Gentile, R. Morelli, E. Lucia, C. Mazzone, A.G. Recchia, N. Vianelli, F. Morabito. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients. Transpl Infect Dis 2010. All rights reserved. Abstract: Leishmaniasis is a zoonosis caused by a protozoan of the Leishmania genus. First-line treatment for all forms is currently represented by the use of antimony derivatives, although toxic effects and the number of resistant strains in both immunocompromised and immunocompetent patients is increasing. Liposomal amphotericin B (L-AMB) is less toxic, more effective, and better tolerated, especially in human immunodeficiency virus-negative immunocompromised patients. We present 2 cases of transplanted patients affected by visceral leishmaniasis treated successfully with L-AMB.
	PMID: 20534035 [PubMed - as supplied by publisher]
	Related citations

6.	Transpl Infect Dis. 2010 May 31. [Epub ahead of print] Visceral leishmaniasis in the early post-transplant period after kidney transplant ation: clinical features and therapeutic management. Veroux M, Corona D, Giuffrida G, Cacopardo B, Sinagra N, Tallarita T, Giaquinta A, Zerbo D, Veroux PF. Department of Surgery, Transplantation, and Advanced Technologies, Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, Catania, Italy. Abstract M. Veroux, D. Corona, G. Giuffrida, B. Cacopardo, N. Sinagra, T. Tallarita, A. Giaquinta, D. Zerbo, P.F. Veroux. Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management. Transpl Infect Dis 2010. All rights reserved Abstract: Visceral leishmaniasis (VL) is a rare complication of kidney transplantation, with <100 cases reported in the literature. It is a life-threatening condition and usually occurs as a late complication after transplantation, with a median delay of 18 months between transplantation and onset of disease. We report the clinical features and management of 5 kidney transplant recipients who presented with VL in the early post-transplant period. All patients were successfully treated with liposomal amphotericin B (L-AMB), but 2 patients experienced graft loss. VL should be considered in the differential diagnosis in kidney transplant recipients living in endemic areas, who present with unexplained fever and pancytopenia in the early post-transplant period. Leishmania serology should be included in the screening of all transplant recipients, in order to identify a group of patients who could benefit from preemptive anti-Leishmania therapy. Therapy with L-AMB is highly effective and well tolerated in kidney transplant recipients with VL.
	PMID: 20534033 [PubMed - as supplied by publisher]
	Related citations